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Pre-exposure prophylaxis (PrEP) for HIV prevention is recommended by the WHO as part of a 
comprehensive HIV prevention package for those at substantial risk of HIV infection[1]. PrEP is 
effective at preventing HIV acquisition, demonstrated by high efficacy in placebo-controlled trials and 
demonstration projects, and increased PrEP coverage is associated with substantial decreases in 
population-level HIV incidence among men who have sex with men (MSM) in high-income settings[2-
4]. Although PrEP is effective in preventing HIV infection, reduced condom use or other increases in 
sexual risk taking risk may increase STI transmission, especially in populations with low PrEP 
adherence, an increase in STIs may play an important role in affecting HIV transmission dynamics. 
Before PrEP was widely available, some urged caution in recommending it because of the potential 
for risk compensation. As cyclists ride faster when made to wear helmets[5], so might PrEP users 
increase condomless sex or sexual partners, increasing the risk of other sexually transmitted 
infections (STIs)[6, 7]. As defined elsewhere[1], risk compensation refers to an increase in risk-
related behaviours, because an intervention reduces perceptions of risk among individuals or a 
population.  
Self-reported condom use and STIs did not change in placebo-controlled PrEP studies[3, 8]. However, 
in some open-label studies where users knew they were taking highly effective PrEP, PrEP use was 
associated with increases in condomless sex and, most importantly, STIs[9]. One observational study 
showed evidence of community-level risk compensation, where MSM not using PrEP also reduced 
condom use as PrEP coverage increased[10]. Importantly, six presentations at the 22nd International 
AIDS Conference in Amsterdam (Table 1) provide further evidence of risk compensation.  
HIV prevention is at a crossroads.. The potential effects of increasing STI incidence must be understood 
alongside the HIV benefits of PrEP, especially with suboptimal adherence or antibiotic-resistant STIs. 
We make an urgent call for more evidence on the potential effect of individual and community-level 
risk compensation on HIV and STI transmission among all groups where PrEP is available, alongside 
proportionate and context-specific programming and communication to mitigate risk compensation.  
First, we do not understand how PrEP will affect epidemic dynamics well enough to make informed 
trade-offs between disease burdens from HIV and STIs. Models have not always predicted HIV 
epidemics accurately to-date[11], and more data are needed to fully understand the long-term impact 
of PrEP in a variety of real-world settings, in order to improve incorrect assumptions which reduce our 
confidence in their projections. Yet modelling is an important component of the health technology 
appraisal process, and will be critical to understand how PrEP’s impact is affected by risk compensation 
 
 
and resulting changes in STI dynamics[12]. There are currently few behavioural data to parameterise 
PrEP models, for example risk compensation may cluster among people with different risk factors (e.g. 
multiple partners or seroconcordance) which are not accurately reflected in sexual mixing 
assumptions. PrEP guidelines also require regular STI testing which could increase early diagnosis and 
treatment, potentially counteracting or even surpassing the effect of any  increases in risky sexual 
behaviour.Second, the majority of evidence on risk compensation exists among MSM groups in high-
income countries. Yet PrEP is now a key part of HIV prevention programmes among other high-risk 
groups, for example adolescent girls and young women in sub-Saharan Africa. We have little evidence 
on risk compensation or PrEP adherence among these groups. The burden of STI acquisition is also 
much higher among women of reproductive age, where chlamydia and gonorrhoea can cause a range 
of reproductive morbidity and display increasing antibiotic resistance. Therefore, the generalisability 
of risk compensation evidence and its implications outside high-income MSM groups is very limited.  
Third, more evidence is needed on the effect of community-level risk compensation; in particular 
sexual behaviours among non-PrEP users in the context of PrEP availability, and early treatment for 
people living with HIV (PLHIV). Risk compensation is unlikely to undermine the HIV prevention benefits 
of PrEP among adherent PrEP users. However, small behavioural changes among non-users may 
reduce PrEP’s overall epidemiological benefit. To model this, it is important to quantify the extent to 
which PLHIV are likely to have undetectable viral loads and/or STIs, particularly in low and middle-
income countries where data is scarce.  
Fourth, more research is needed on how users understand PrEP as a complement or substitute for 
alternate prevention strategies. Although guidelines recommend that PrEP users be counselled to 
use condoms, these are inconsistent since eligibility criteria for PrEP include reporting inconsistent 
condom use. Different, effective alternatives may therefore be needed to prevent STIs alongside 
PrEP, as  condoms may be hard to promote among people who are primarily concerned with HIV 
prevention.  The extent to which PrEP is used as a substitute to condoms, is likely to vary between 
populations and contexts. It is critical that we understand behavioural and structural approaches 
that support the provision of combination prevention services and tailored prevention packages. 
Finally, where intermittent PrEP is provided, evidence is needed to understand behaviours before, 
during, and between episodes of use. Since intermittent PrEP regimens depend partly on user risk 
perception, it is important to understand how the choice to use PrEP is made, and how time on PrEP 
impacts risk behaviours surrounding episodes of PrEP use. Importantly, risk perceptions are rarely 
measured but inferred from behaviour change without knowing why behaviours changed – more work 
on measuring risk changing risk perceptions is needed. 
PrEP has an important role in HIV prevention, and uncertainty in its effect on risk compensation and 
STI incidence should not prevent provision to those at high risk. Nonetheless, in order to support 
effective PrEP programming, researchers and practitioners need reliable and robust behavioural 
evidence from all populations to evaluate its true risks and benefits. 
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Authors Title Study 
Population, 
Location 
Evidence type  Findings related to risk compensation 
Rendina et al. 
http://programme.aids2018.org/ 
Abstract/Abstract/8121 
Changes in rectal STI incidence 
and behavioral HIV risk before, 
during, and after PrEP in a 
national sample of gay and 











• No change in odds of rectal STI during PrEP use or after 
discontinuation compared to before uptake 
• Compared to before PrEP use: 
o 156% increase in condomless anal sex with casual 
partners 
o 410% increase in receptive condomless anal sex with 
serodiscordant male partners while on PrEP, but 
average of <1 act per person 
De Wit et al. 
http://programme.aids2018.org/ 
Abstract/Abstract/10801 
Attitudes regarding HIV, PrEP 
and condom use jointly 
predict risk compensation 
among men who have sex 








• Frequency of condom use for anal sex with causal 
partners decreased significantly over one year follow up 
• Median condom protected acts in last three months 
reduced from 3 to 2  
 
Traeger et al. 
http://programme.aids2018.org/ 
Abstract/Abstract/3905 
Changes, patterns and 
predictors of sexually 
transmitted infections in gay 
and bisexual men using PrEP; 
interim analysis from the 







• STI incidence (chlamydia, gonorrhea, syphilis, and rectal 
pharyngeal or urethral infections) increased after PrEP 
use compared to before (IRR: 1.42 95%CI: 1.29-1.56) 
 
Molina et al. 
http://programme.aids2018.org/ 
Abstract/Abstract/13278 
Incidence of HIV-infection in 
the ANRS Prevenir Study in the 
Paris Region with Daily or On 






• Indicative (not statistically tested) evidence of 
behavioural risk compensation (condomless sex at last 
intercourse, number of condomless acts in previous 4 
weeks)  
 
Prestage et al. 
http://programme.aids2018.org/ 
A longitudinal analysis of the 





• Among PrEP users significant increase in: 
o Condomless anal sex (78% increase) 
 
 




Abstract/Abstract/8042 behaviour and drug use 




o number of partners in previous six months 
(100% increase) 
o Proportion reporting group sex (96% increase) 
Morris et al. 
http://programme.aids2018.org/ 
Abstract/Abstract/11478 
High HIV PrEP adherence is 







 • The incidence rate of syphilis was over 3 times higher 
among those highly adherent (≥1246 fmol/punch, 
consistent with 7 doses per week or near perfect 
dosing) to TFV-DP at week 12 and week 48, compared to 
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